How do age, life circumstances, comorbidities, concomitant medications, and subjective preferences influence the selection of drug classes approved for monotherapy of early-stage PD (levodopa, dopamine agonists, MAO-B-inhibitors, amantadine, anticholinergics)? The gene discussed is MAOB; the disease is Parkinson disease.